Archives of Clinical Infectious Diseases
Farzin Khorvash1,*, 
Kamyar Mostafavizadeh1, Sina Mobasherizadeh1, Mohaddeseh Behjati1, Mansoor Salehi2The rapid emergence of antibiotic resistance, especially broad-spectrum antibiotics, resulted in the avid use of new potent antibiotics. Ceftriaxone and ceftazidime, two third-generation cephalosporin, are usually used to manage complicated and uncomplicated infections. The use of cefepime in resistant infections is increasing gradually, which put this potent antibiotic at risk of resistance.
During an 18-month period, a total of 220 gram-negative bacteria including Pseudomonas spp, Serratia spp, Acinetobacter spp, Proteus spp, E-coli and Klebsiella spp. have been isolated by standard microbiological methods from nosocomial surgical site, abscess, blood stream and urinary tract infections. MIC of antibiotics on isolated bacteria was determined by gradient concentration method.
Totally, 29.4%, 19.5% and 23.3% of isolated bacteria with MIC?8?g/ml were sensitive to cefepime, ceftriaxone and ceftazidime, respectively. High level resistance with MIC?256?g/ml to cefepime, ceftriaxone and ceftazidime was also observed in 47.1%, 70.8% and 62.5% of cases, respectively (p<0.05). High level resistance to cefepime were more commonly observed for pseudomonas (73.1%) and Klebsiella spp. (73.5%), respectively (p<0.05).
© 2009, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Purchasing Reprints
Author(s):
